Aptorum Group Ltd. (APM) Stock Price, Financials & Summary

Price chart

Jul 31Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31

Key dataAug 31, 2026

Open$6.69

From 52W high−65.73%

Volume94803.00

Market cap$67.27M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataAug 31, 2026

Open

$6.69

From 52W high

−65.73%

Volume

94803.00

Market cap

$67.27M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

35.0

MomentumView details →

1D Return

−14.84%

YTD Return

−35.28%

SummaryUpdated Jun 1, 2026

Aptorum Group Limited (NASDAQ:APM) is a London-headquartered biopharmaceutical company that was incorporated in 2010 and went public in December 2018. The company focuses on discovering, developing, and commercializing therapeutic products primarily for infectious diseases and cancer treatment. As a clinical-stage biotechnology firm, Aptorum operates with a diverse pipeline of drug candidates spanning multiple therapeutic areas including oncology, infectious diseases, neurology, and metabolic disorders, while also maintaining a small medical clinic operation.

Ask drillr about Aptorum Group Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1431.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

1494.72%

ROA (TTM)

4.10%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+54.55%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+75.64%

EBITDA YoY

+100.00%

MomentumView details →

1D Return

−14.84%

YTD Return

−35.28%

1Y Return

−63.12%

RSI (14)

35.0

vs 50D SMA

−17.87%

vs 200D SMA

−27.73%

Capital & dividendView details →

Debt/Equity

74.65x

Current Ratio

0.45x

Quick Ratio

0.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.06

EPS Surprise

—

Beats (12Q)

7/12

Next Q EPS Est

—

Avg Surprise (4Q)

65.34%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

960817.00

Net Income (TTM)

−6.39M

Op. CF (TTM)

—

Latest newsMore news →

Aptorum Group provided an update on its merger with DiamiR Biosciences, resulting in the post-merger company Niki BioSolutions, Inc. trading on Nasdaq under ticker NIKI.66d ago

Aptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate biomarker data for Alzheimer's disease.90d ago

Similar companies

XBiotech Inc.XBIT Alps Group IncALPS Apollomics, Inc.APLM Pliant Therapeutics, Inc.PLRX Spero Therapeutics, Inc.SPRO Gossamer Bio, Inc.GOSS Find similar companies →

Latest newsMore news →

Aptorum Group provided an update on its merger with DiamiR Biosciences, resulting in the post-merger company Niki BioSolutions, Inc. trading on Nasdaq under ticker NIKI.66d ago Aptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate biomarker data for Alzheimer's disease.90d ago Aptorum Group shareholders approved a merger with DiamiR Biosciences.102d ago